SynthesisThe Journal of infectious diseases2025
Effectiveness of MenB-4C Vaccine Against Gonorrhea: A Systematic Review and Meta-analysis.
Synthesis in The Journal of infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Preclinical Evaluation of Novel ConservedVaccines · 2026Article
- An mRNA-Lipid Nanoparticle Platform Encoding the Conserved Outer Membrane Protein BamA Elicits Broadly Cross-Reactive Systemic and Mucosal Antibodies Against Antimicrobial-ResistantbioRxiv : the preprint server for biology · 2026Article
- Potential Use of Neisseria meningitidis Serogroup B Vaccines to Prevent Neisseria gonorrhoeae Infection: Epidemiological Considerations.Journal of the International AIDS Society · 2026Review
- Plasmids inClinical microbiology reviews · 2026Review
- Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO).NPJ vaccines · 2026Article
- Perspective on the pathogenic Neisseria: milestones, challenges, and future directions.NPJ vaccines · 2026Review
- Gonorrhea Management in High-, Limited- and No-Resource Settings: Implications in the Context of Antimicrobial Resistance.International journal of dermatology · 2026Review
- Repurposing epetraborole to combatAntimicrobial agents and chemotherapy · 2026Article
- Pre-clinical efficacy of a C4BP hexameric IgG Fc fusion protein against Neisseria gonorrhoeae.PloS one · 2026Article
- Updates on Testing, Treatment, and Prevention of Sexually Transmitted Infections in the United States, 2025.Topics in antiviral medicine · 2025Review
- Joint consensus on reducing the burden of invasive meningococcal disease in the Asia-Pacific region.Human vaccines & immunotherapeutics · 2025Review
- Structure-based engineering of a nutrient acquisition protein enhances neutralizing antibodies and protection for the development of a gonococcal vaccine.bioRxiv : the preprint server for biology · 2025Article
- Review
- The gonococcal vaccine candidate antigen NGO1701 is a N. gonorrhoeae periplasmic copper storage protein.PLoS pathogens · 2025Article
- CommensalAnnual review of microbiology · 2025Review
- Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness.NPJ vaccines · 2025Article
- Potential public health impacts of gonorrhea vaccination programmes under declining incidences: A modeling study.PLoS medicine · 2025Article
- PreclinicalFrontiers in immunology · 2025Article
- An oropharyngeal gonorrhoea controlled human infection model: a provisional protocol using a novelWellcome open research · 2025Article
- Vaccines as Potential Frontliners Against Antimicrobial Resistance (AMR): A Focused Review.Infection and drug resistance · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThere is no licensed vaccine against gonorrhea, but Neisseria meningitidis serogroup B outer membrane vesicle-based vaccines, such as MenB-4C, may offer cross-protection against gonorrhea. This systematic review and meta-analysis synthesized the published literature on MenB-4C vaccine effectiveness against gonorrhea.
methodsWe conducted a literature search of electronic databases (PubMed, Medline, Embase, Global Health, Scopus, Google Scholar, CINAHL, and Cochrane Library) to identify peer-reviewed articles published in English from 1 January 2013 to 11 September 2024 that reported MenB-4C vaccine effectiveness estimates against gonorrhea and gonorrhea/chlamydia coinfection and the duration of MenB-4C vaccine-induced protection. We estimated pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea using the DerSimonian-Laird random effects model.
resultsEight articles met our eligibility criteria. Receipt of ≥1 dose of MenB-4C vaccine was 23% to 47% effective against gonorrhea. Two doses of MenB-4C vaccine were 33% to 40% effective against gonorrhea, and 1 dose of MenB-4C vaccine was 26% effective. MenB-4C vaccine effectiveness against gonorrhea/chlamydia coinfection was mixed, with 2 studies reporting effectiveness estimates of 32% and 44% and 2 other studies showing no protective effect. MenB-4C vaccine effectiveness against gonorrhea was comparable in people with HIV (44%) and people without HIV (23%-47%). Pooled MenB-4C vaccine effectiveness (≥1 dose) against gonorrhea was 32.4%. One study concluded that MenB-4C vaccine effectiveness against gonorrhea may wane approximately 36 months postvaccination.
conclusionsMenB-4C vaccine is moderately effective against gonorrhea in various populations. Prospective clinical trials that assess the efficacy of MenB-4C against gonorrhea, gonorrhea/chlamydia coinfection, and duration of protection are warranted to strengthen this evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.